Morning Briefing
Summaries of health policy coverage from major news organizations
15% Of US Adults Have Used GLP-1s For Weight Loss, Poll Finds
The number of people injecting themselves with or taking an oral version of the new class of weight-loss drugs continues to rise dramatically. A Gallup poll released Tuesday based on a web survey of 5,065 U.S. adults says that 15 percent of U.S. adults reported using GLP-1 medications to lose weight at some point, while 11 percent say they currently are taking them. That’s up from a Gallup poll in 2024 that found 6 percent had ever taken them, and 3 percent were currently on the therapy. (Rowland, 7/7)
More pharma and tech news —
The Food and Drug Administration on Tuesday approved a new medicine from the biotech company Vera Therapeutics for patients with a type of chronic autoimmune kidney disease. (Feuerstein, 7/7)
An investigational vaccine candidate for Shigella provided high-level protection in a phase 2 clinical trial, researchers reported last week in The Lancet Infectious Diseases. (Dall, 7/7)
You get a CGM, you get a CGM, everybody gets a CGM? For the first time in the United States, children 2 and older can also get a continuous glucose monitor without a doctor’s prescription. Is that a good thing? The Food and Drug Administration thinks so. (Chan, 7/8)
The charges for most of the people carry sentences of up to 12.5 years in prison, officials said, and the police have recommended more charges for a separate attempt in April. (Rubin, 7/7)
